Related Experiment Video

Updated: May 20, 2026

Sub-acute Cerebral Microhemorrhages Induced by Lipopolysaccharide Injection in Rats
06:39

Sub-acute Cerebral Microhemorrhages Induced by Lipopolysaccharide Injection in Rats

Published on: October 17, 2018

Clinical aspects of microbleeds in Alzheimer's disease

Wiesje M van der Flier1

  • 1Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands. wm.vdflier@vumc.nl

Journal of the Neurological Sciences
|July 28, 2012
PubMed

Insights

Microbleeds, small brain lesions common in Alzheimer's disease (AD), may worsen cognitive impairment. However, evidence is unclear if they impact disease progression, possibly due to study limitations like mortality bias.

Area of Science:

  • Neurology
  • Radiology
  • Neurodegenerative Diseases

Background:

  • Microbleeds are frequently observed in Alzheimer's disease (AD) patients.
  • Their clinical significance in AD remains incompletely understood.
  • Radiologically, microbleeds appear as small, dark spots on T2-weighted MRI scans.

Purpose of the Study:

  • To review current evidence on the clinical relevance of microbleeds in Alzheimer's disease.
  • To assess the association between microbleeds and cognitive impairment severity in AD.
  • To evaluate the impact of microbleeds on disease progression in AD and mild cognitive impairment (MCI).

Main Methods:

  • Systematic review of existing literature on microbleeds in AD.
  • Analysis of studies correlating microbleed presence and location with cognitive function.
  • Examination of research investigating microbleed effects on disease progression in MCI and AD.

Main Results:

  • Evidence suggests multiple microbleeds may negatively affect cognitive performance in AD.
  • Consensus is lacking regarding the influence of microbleed location on cognitive severity.
  • Limited evidence indicates microbleeds do not significantly affect disease progression rates in MCI or AD.

Conclusions:

  • Microbleeds might be associated with cognitive decline severity in Alzheimer's disease.
  • The impact of microbleeds on the progression of Alzheimer's disease is not clearly established.
  • Methodological limitations, including mortality bias, may influence findings on disease progression.

More Related Videos

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

Using Retinal Imaging to Study Dementia09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.